PT-141 (Bremelanotide): The First Centrally Acting Drug For Sexual Desire

PT-141, also known as bremelanotide, is a synthetic cyclic peptide that acts on melanocortin receptors in the brain to drive sexual desire and arousal, making it mechanistically unlike every other pharmaceutical approach to sexual dysfunction.

In this post, we will discuss what PT-141 is, how the melanocortin system governs sexual behavior, the mechanism of action, clinical trial data in women and men, pharmacokinetics, side effects, dosing, and the genetics of melanocortin receptor variability.

What PT-141 Is

PT-141 (generic name: bremelanotide; brand name: Vyleesi) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous neuropeptide that regulates pigmentation, energy balance, inflammation, and sexual behavior. R

It was FDA-approved on June 21, 2019 (NDA 210557) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. R

Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Molecular weight: approximately 1,025 Da

Cyclization: lactam bridge between Asp and Lys residues confers metabolic stability far exceeding linear alpha-MSH analogs R

Origin:

In the 1950s and 1960s, Ferrari and colleagues showed that central administration of alpha-MSH and ACTH induced sexual excitement and penile erection across multiple experimental species. R

The connection to human clinical development came serendipitously during early testing of Melanotan II (MT-II), a synthetic cyclic analog of alpha-MSH designed as a sunless tanning agent.

During clinical testing at the University of Arizona, dermatologist Norman Levine observed that male subjects receiving MT-II experienced unexpected spontaneous erections. R

This observation prompted formal study of MT-II in men with erectile dysfunction (ED), which then led to the development of PT-141 as a deaminated derivative and likely metabolite of MT-II that retained pro-sexual effects with an improved formulation profile. R

PT-141 is the carboxylate derivative of MT-II, lacking the C-terminal amide group. R

---

The Melanocortin System

Understanding what PT-141 does requires a working model of the melanocortin system.

The five melanocortin receptors (MC1R through MC5R) are all G-protein coupled receptors signaling primarily through cAMP. R

Their tissue distribution and primary functions are: (not exhaustive list)

• MC1R (skin and hair follicles): controls pigmentation; also targeted by PT-141, explaining hyperpigmentation as a side effect R
• MC2R (adrenal gland): the ACTH receptor; PT-141 has minimal activity here R
• MC3R (hypothalamus and limbic system): involved in energy balance and sexual behavior R
• MC4R (widely expressed throughout the CNS): primary mediator of sexual function, energy homeostasis, and cardiovascular regulation R
• MC5R (exocrine glands): sebum production and secretory functions R

PT-141 is a non-selective agonist across MC1R through MC5R.

At therapeutic doses, binding to MC1R and MC4R is most relevant. R

MC4R and sexual function:

MC4R is predominantly expressed in the medial preoptic area (mPOA) and paraventricular nucleus (PVN) of the hypothalamus. R

MC4R knockout animals show abolished erectogenic responses to melanocortin agonists, establishing this receptor as an essential mediator of the sexual arousal response. R

In anesthetized rabbits, the MC3R/MC4R antagonist SHU 9119 abolished MT-II-induced increases in intracavernosal pressure, confirming that pro-erectile melanocortin effects require these receptor subtypes. R

The POMC-AgRP axis:

The melanocortin system involves two opposing hypothalamic neuron populations. R

POMC (pro-opiomelanocortin) neurons release alpha-MSH and related peptides that activate MC3R and MC4R to drive pro-sexual signaling.

AgRP (agouti-related protein) neurons release AgRP, an endogenous inverse agonist at MC3R and MC4R that opposes POMC signaling and is associated with feeding and inhibition of sexual motivation.

The balance between POMC and AgRP neuronal activity determines melanocortinergic tone in the hypothalamus. R

The MC3R question:

The role of MC3R in pro-sexual signaling is not cleanly resolved.

MC3R-specific agonists have failed to produce significant erections in animal models.

Novel data suggest that antagonism of forebrain MC3R may actually enhance melanocortin-induced erections, implying MC3R may act as an inhibitory brake on the MC4R-driven pro-sexual signal in some hypothalamic circuit configurations. R

This biology is not yet settled and the weight of evidence leans toward MC4R as the principal effector. R

---

Clinical Evidence: Women (HSDD)

What HSDD is:

HSDD is defined as persistent diminished or absent desire for sexual activity accompanied by personal distress or interpersonal difficulty. R

Women with HSDD display lack of motivation for sexual activity, reduced responsiveness to erotic cues, loss of interest during sexual activity, and avoidance of situations that could lead to sexual activity. R

The FDA approval covers specifically acquired, generalized HSDD without an identifiable underlying medical, psychiatric, or relationship cause. R

Early Phase 2 data:

A 2006 randomized controlled trial enrolled 18 premenopausal women with female sexual arousal disorder and administered a single intranasal dose of 20 mg bremelanotide or placebo. R

More women reported moderate or high sexual desire following bremelanotide versus placebo (P = 0.0114). R

Among women who attempted sexual intercourse within 24 hours, significantly more were satisfied with their level of sexual arousal following bremelanotide versus placebo (P = 0.0256). R

Vaginal vasocongestion measured by photoplethysmography did not change significantly, suggesting PT-141's primary effect is on the subjective experience of desire rather than on peripheral genital blood flow, consistent with a central mechanism. R

A phase 2b dose-finding trial in 397 premenopausal women with HSDD, female sexual arousal disorder, or both, showed subcutaneous bremelanotide taken as needed for up to 12 weeks produced dose-responsive improvements in desire, arousal, and distress, as well as increases in the number of satisfying sexual events compared to placebo. R

RECONNECT Phase 3 Trials:

Two identical Phase 3, randomized, double-blind, placebo-controlled, multicenter trials (RECONNECT Studies 301 and 302) evaluated bremelanotide 1.75 mg subcutaneously as needed in premenopausal women with HSDD over 24 weeks. R

Total enrolled: 1,267 women randomized; the modified intent-to-treat efficacy population included 1,202 women. R

Participants were required to have acquired, generalized HSDD for at least 6 months, prior history of normal sexual function for at least 2 years, and willingness to engage in sexual activity at least once per month during the study. R

Co-primary endpoints:

The two co-primary endpoints were change from baseline to end of study in: R

• FSFI-D (Female Sexual Function Index desire domain score): subjective desire
• FSDS-DAO item 13 (Female Sexual Distress Scale): distress related to low desire

Both endpoints were met with statistical significance in both studies (integrated population P < 0.001 for both). R

Effect size:

The treatment difference in FSFI-D was 0.35 and in FSDS-DAO Item 13 was 0.33 (bremelanotide minus placebo). R

The Cohen's d effect size for improving sexual desire was 0.39, and for decreasing distress was 0.27. R

A Cohen's d of 0.39 is a small-to-medium effect by conventional standards.

These effect sizes are comparable to those reported for flibanserin (Addyi), the other FDA-approved HSDD treatment, which showed Cohen's d values in the range of 0.29 to 0.44 for desire improvement. R

Researchers have questioned whether these improvements on rating scales translate to clinically meaningful changes in patients' sexual lives, and this is a valid, ongoing methodological debate. R

Subgroup consistency:

Bremelanotide produced statistically significant improvements in sexual desire regardless of hormonal contraceptive use, regardless of whether decreased arousal was also present, and regardless of HSDD duration. R

Long-term data:

A 52-week open-label extension enrolled 684 eligible participants from the RECONNECT core phase. R

Efficacy was maintained over the full 52 weeks without attenuation.

The most common treatment-emergent adverse events related to study drug were nausea (40.4%), flushing (20.6%), and headache (12.0%), consistent with the core phase data. R

---

Clinical Evidence: Men (Erectile Dysfunction)

PT-141 is not FDA-approved for male sexual dysfunction, but Phase 1 and Phase 2 clinical trial data exist.

Phase 1 in healthy men:

A Phase 1 randomized, double-blind, placebo-controlled trial in 24 healthy men without ED delivered intranasal PT-141 in the absence of visual sexual stimulation. R

Doses above approximately 7.5 mg produced significant dose-dependent increases in erectile activity measured by RigiScan penile tumescence monitoring.

Erections occurred without visual stimulation, demonstrating that central MC4R activation alone is sufficient to initiate the erectile response. R

Phase 2a in sildenafil non-responders:

Subcutaneous PT-141 at 4 mg and 6 mg produced statistically significant erectile responses in men with ED who had an inadequate response to sildenafil, measured by RigiScan. R

In the bremelanotide group, 34% reported significantly better results including ability to achieve and maintain erection sufficient for intercourse, compared to 9% on placebo. R

Why PT-141 helps PDE5 non-responders:

Many cases of so-called Viagra failure are not caused by insufficient penile blood flow but by insufficient central arousal drive. R

PDE5 inhibitors (phosphodiesterase type 5 inhibitors) require endogenous nitric oxide release (which requires sexual arousal signals to reach cavernous nerves) before they can amplify the erection.

If the central arousal signal is absent or insufficient (as in psychogenic ED, low-desire ED, or ED with a neurological component), PDE5 inhibitors provide no substrate to amplify.

PT-141 initiates the arousal cascade centrally, providing that substrate even when subjective desire is diminished. R

Combination with PDE5 inhibitors:

A combination trial administered low-dose intranasal PT-141 (7.5 mg) with low-dose sildenafil (25 mg).

The erectile response from the combination was significantly greater than from sildenafil alone without increased adverse events. R

This synergism is mechanistically coherent: PT-141 drives the central neural cascade via MC4R while sildenafil amplifies the peripheral cGMP response at the downstream end of that cascade.

Androgen dependence caveat:

The pro-erectile effects of melanocortins in animal models are androgen-dependent: castration abolishes the erectile response to alpha-MSH and ACTH, and testosterone replacement restores it. R

Men with hypogonadism may not respond adequately to PT-141 because the androgen environment required for downstream neurovascular signaling is insufficient.

Testosterone optimization is a logical prerequisite in men with low T before trialing PT-141.

---

Pharmacokinetics

Absorption:

Subcutaneous bioavailability is approximately 100%. R

Maximum plasma concentration occurs approximately 1 hour after subcutaneous injection (range 0.5 to 1.0 hours). R

After a 1.75 mg subcutaneous dose, mean maximum plasma concentration reaches 72.8 ng/mL and AUC is 276 hr*ng/mL. R

Distribution:

Plasma protein binding is 21%, meaning most circulating bremelanotide is unbound and biologically available. R

Metabolism:

Bremelanotide is metabolized primarily via hydrolysis of its peptide bonds by peptidases. R

It does not undergo significant CYP450-mediated hepatic metabolism, which limits the drug-drug interaction profile for most medications.

However, bremelanotide slows gastric motility, which can reduce the rate and extent of absorption of concomitantly administered oral medications. R

Clinically meaningful reductions in oral absorption have been documented for naltrexone and indomethacin specifically. R

Elimination:

Half-life: 2.7 hours (range 1.9 to 4.0 hours). R

Excretion: 64.8% in urine, 22.8% in feces. R

Hepatic impairment:

AUC increases 1.2-fold in mild hepatic impairment (Child-Pugh A) and 1.7-fold in moderate impairment (Child-Pugh B). R

The effect of severe hepatic impairment has not been studied.

Alcohol:

Unlike flibanserin (Addyi), bremelanotide does not have a clinically significant pharmacokinetic interaction with alcohol. R

A dedicated study found no significant increases in adverse events and no clinically significant blood pressure changes when bremelanotide was combined with ethanol, which is a meaningful practical advantage over flibanserin for which the alcohol interaction is a major prescribing barrier. R

---

Side Effects And Safety

Common adverse effects from RECONNECT long-term data: (not exhaustive list) R

• Flushing (20.6%)
• Headache (12.0%)
• Injection site reactions (13.2%)
• Nausea (40.4%): most common; most frequently mild to moderate and transient; primary driver of discontinuation
• Vomiting (4.8%)

Most adverse events were mild to moderate in intensity. R

Blood pressure:

Bremelanotide produces a transient increase in blood pressure that has been consistent across all studies. R

Mean increases: approximately 6 mmHg systolic and 3 mmHg diastolic, peaking within approximately 4 hours and returning to baseline by approximately 8 to 10 hours. R

A concurrent transient decrease in heart rate is also observed. R

Due to these cardiovascular effects, bremelanotide is contraindicated in individuals with uncontrolled hypertension or known cardiovascular disease. R

Hyperpigmentation:

MC1R stimulation increases melanin expression, which can produce hyperpigmentation particularly with frequent use. R

This effect can occur on the face, gums, or breasts. R

It may not fully resolve upon stopping the drug, which distinguishes it from most other drug-related skin side effects. R

Patients with darker baseline skin tones may be at higher risk.

Hepatotoxicity (rare):

Bremelanotide has been reported to cause mild serum enzyme elevations during therapy and has been implicated in rare instances of clinically apparent acute liver injury, including one case of acute icteric hepatitis in the open-label extension phase. R

This is a rare event, but it warrants monitoring in patients with pre-existing hepatic issues or on hepatotoxic medications.

Genotoxicity and fertility:

Bremelanotide was not genotoxic or mutagenic in standard battery tests. R

No effects on fertility were observed in male or female mice at doses approximately 375 and 760 times the human AUC respectively. R

---

Dosing And Administration

FDA-approved protocol (premenopausal women with HSDD):

Bremelanotide 1.75 mg subcutaneously injected in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. R

Maximum: one dose per 24 hours, no more than 8 doses per month. R

Discontinue after 8 weeks if there is no improvement in sexual desire and associated distress. R

Formulation: prefilled autoinjector pen in 0.3 mL solution (1.75 mg bremelanotide equivalent to 1.89 mg bremelanotide acetate).

Off-label male dosing:

Male dosing is not established in any FDA-approved guidance.

Phase 2 trials in men used subcutaneous doses of 4 to 6 mg, administered approximately 45 to 60 minutes before anticipated sexual activity. R

Melanotan II warning:

Melanotan II, the parent compound from which PT-141 was derived, is not FDA-approved for any use.

Melanotan II has been associated with unpredictable nausea, blood pressure changes, alterations to existing nevi, and has not undergone the systematic clinical trial safety evaluation that bremelanotide has completed. R

Melanotan II and PT-141 are not the same compound and must not be substituted for one another.

---

Mechanisms Of Action

Simple:

• PT-141 activates MC4R in the hypothalamus, specifically in the medial preoptic area (mPOA) and paraventricular nucleus (PVN), increasing dopamine release and driving the subjective experience of sexual desire R
• This central signal propagates via oxytocinergic neurons in the PVN to the spinal cord, where it activates nitric oxide synthase in penile cavernous nerves, producing the neurogenic erection cascade R
• Unlike PDE5 inhibitors, PT-141 does not require the user to be already sexually aroused before it is effective; it initiates the arousal signal upstream of any peripheral vascular response R
• MC1R activation on melanocytes causes the hyperpigmentation side effect by increasing melanin synthesis R
• The pro-sexual effects of melanocortin agonists are androgen-dependent in animal models; testosterone optimization is a prerequisite for adequate response in hypogonadal men R

Advanced:

MC4R-cAMP-PKA signaling:

When PT-141 binds MC4R, the receptor couples to stimulatory Gs protein, activating adenylyl cyclase and increasing intracellular cAMP. R

Elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream targets that alter neuronal excitability in MC4R-expressing hypothalamic neurons. R

This shifts the excitability state of mPOA and PVN neurons toward a pro-sexual configuration.

The dopamine pathway:

Activation of presynaptic MC4R on neurons in the mPOA increases dopamine release into the medial preoptic area. R

Dopamine in the mPOA is a principal mediator of sexual motivation (the "wanting" component), which is distinct from the hedonic response to sexual stimulation (the "liking" component). R

This is why PT-141's primary clinical effect in women is characterized as enhanced desire rather than merely improved peripheral arousal: the drug targets the motivational circuitry upstream of any genital response. R

The oxytocin-nitric oxide bridge:

POMC neurons in the PVN contain both oxytocinergic projections and MC4R expression. R

Activation of MC4R on these PVN neurons increases oxytocin release into extra-hypothalamic brain areas including the brainstem and spinal cord. R

Oxytocin at spinal level activates nitric oxide synthase (NOS) in neurons projecting to the pelvic plexus.

NOS-derived nitric oxide (NO) is released from cavernous nerve terminals in the corpus cavernosum, activating soluble guanylate cyclase (sGC), producing cGMP, and relaxing smooth muscle to allow blood inflow. R

This is the same final cGMP-effector pathway that PDE5 inhibitors act on by preventing cGMP degradation.

PT-141 initiates this pathway centrally via the MC4R-oxytocin-NOS axis; PDE5 inhibitors amplify it peripherally by blocking phosphodiesterase 5.

When combined at lower doses, the two mechanisms are complementary rather than redundant, explaining the synergy observed in combination trials. R

The MC3R inhibitory constraint:

Antagonism of forebrain MC3R in animal models paradoxically enhances melanocortin-induced erections when combined with MC4R agonism. R

One proposed configuration is that AgRP neurons activated by MC3R on POMC neuron feedback loops may partially brake the pro-erectile output from MC4R-expressing downstream neurons.

PT-141's partial MC3R agonism may therefore slightly limit its own MC4R-mediated sexual effect in forebrain circuits, which could explain the hormetic-like dose-response pattern and the relatively modest effect sizes seen in clinical trials despite robust preclinical data. R

---

Genetics

MC4R variants:

MC4R loss-of-function variants are the most common cause of monogenic obesity, present in approximately 1 to 6% of severely obese patients.

Individuals with MC4R haploinsufficiency or loss-of-function variants would be expected to have blunted or absent responses to PT-141, because the primary receptor through which it acts is constitutively underactive.

Conversely, MC4R activating variants, if present, might enhance PT-141 responses, though this has not been studied.

POMC variants:

The POMC gene encodes the precursor to alpha-MSH.

Rare POMC loss-of-function variants cause severe early-onset obesity and adrenal insufficiency, with impaired melanocortin signaling throughout the system.

Carriers of milder POMC variants affecting alpha-MSH production would have reduced endogenous melanocortinergic tone, potentially lowering baseline sexual motivation and making them more responsive to exogenous MC4R agonism with PT-141.

AgRP variants:

AgRP is the endogenous inverse agonist at MC3R and MC4R that opposes POMC-driven melanocortin signaling.

AgRP promoter polymorphisms that increase AgRP expression would suppress the melanocortin-sexual arousal axis and could be associated with lower baseline sexual desire.

PT-141 efficacy in individuals with elevated AgRP activity would depend on whether the exogenous MC4R agonist concentration can overcome the elevated endogenous antagonist tone.

MC1R variants and hyperpigmentation risk:

MC1R is highly polymorphic.

"Red hair color" (RHC) variants associated with fair skin, red hair, and impaired tanning response indicate reduced baseline MC1R signaling.

Individuals with RHC variants may be at lower risk for hyperpigmentation from PT-141, while those with constitutively more active MC1R genotypes (darker baseline pigmentation) may be at higher risk for persistent hyperpigmentation with repeated use.

Androgen receptor variants:

Given the androgen-dependence of melanocortin pro-erectile effects in animal models, androgen receptor (AR) variants affecting testosterone sensitivity would be expected to modulate PT-141 efficacy in men. R

Men with CAG repeat length expansions in the AR gene (associated with reduced androgen sensitivity) may respond less robustly to PT-141 even with normal circulating testosterone.

---

More Research

• PT-141 for male ED: Phase 3 gap. Phase 2 data in sildenafil non-responders is compelling but no Phase 3 trial has been completed for this indication. R A combination trial combining PT-141 with PDE5 inhibitors in treatment-resistant ED, if positive, could support regulatory filing for this indication and address an unmet need in approximately 30 to 40% of men who fail first-line PDE5 inhibitor monotherapy. R

• Postmenopausal HSDD. The FDA approval is limited to premenopausal women, but HSDD is also prevalent in postmenopausal women where declining estrogen and testosterone further reduce desire. R The melanocortin arousal pathway does not obviously depend on estrogen for its central effects, making postmenopausal women a logical label expansion population. Phase 3 data in this group does not yet exist.

• Selective MC4R agonists. PT-141's MC1R activity drives hyperpigmentation, a meaningful tolerability concern for long-term or frequent use. Setmelanotide (Imcivree) is an FDA-approved selective MC4R agonist developed for rare genetic obesity syndromes, demonstrating that receptor selectivity over MC1R is achievable. R Whether a more selective MC4R agonist can retain bremelanotide's pro-sexual effects while reducing hyperpigmentation and blood pressure effects is an open clinical development question.

• Validation of the desire/arousal dissociation. The 2006 Phase 2 trial finding of improved subjective desire without a significant change in vaginal vasocongestion was the first controlled demonstration that female sexual desire can be pharmacologically enhanced through a central mechanism that is dissociable from peripheral genital arousal. R This dissociation has implications for understanding the neurobiology of desire versus arousal in women, particularly the question of whether these two dimensions are served by separable neural circuits that can be independently targeted therapeutically.